OncLive TV

Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Noman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

R. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.

Daniel E. Haggstrom, MD, discusses future research directions within EGFR-and ALK-mutant non–small cell lung cancer.

Jairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

Kathleen N. Moore, MD, MS, discusses the evolving landscape in managing platinum-resistant ovarian cancer.

Tanios Bekaii-Saab, MD, FACP, discusses the role of liquid and tissue biopsies in newly diagnosed gastrointestinal cancers.

Deena Mary Atieh Graham, MD, discusses a pilot study evaluating RAGE inhibition to reduce therapy-related cardiotoxicity in early-stage breast cancer.

Rupesh Rajesh Kotecha, MD, discusses the FDA approval for Optune Lua in metastatic non–small cell lung cancer.

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.

Daniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.

Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.

Kenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.

Piotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.